Beigene Ltd., of Beijing, presented initial data from an ongoing phase I dose-escalation trial of BGB-A317 in patients with advanced solid tumors. BGB-A317 is a humanized monoclonal antibody against the immune checkpoint inhibitor PD-1. The preliminary data show that BGB-A317 is well-tolerated and demonstrates antitumor activity in a range of advanced solid tumors.